




2Q22 Results Presentation



viveo

Pharmacy unlike anything you've ever seen!



Over 900 thousand km per month and deliveries across the national territory



Expansion of the services offered to customers.

Handling of sterile solutions

An ecosystem of care in Brazil

viveo

Present in the supply chain from manufacturing to delivering to the patient

Complete solution for laboratory items



Vaccines and Laboratories' channel distributor



Reference in trust and quality in the vaccine market



Over 85 years of reference in product quality and innovation

Distributors of Hospitals' channel



Complete portfolio of materials and medicines with national reach and high level of service

*Expressa – CNPJ represented by the trademark Mafra Hospitalar.

**PointMed – CNPJ represented by the trademark Tecno4.

***BEMK – CNPJ represented by the trademark MedCare.

Second consecutive quarter with record Adjusted Ebitda Margin



NET REVENUE

- BRL1,946.2 million in 2Q22 – up 32.9% from 2Q21
- BRL3,846.1 million in 1H22 – up 30.4% from 1H21

GROSS PROFIT

- BRL324.0 million in 2Q22 – up 47.9% from 2Q21: margin 16.7%
- BRL622.3 million in 1H22 – up 47.2% from 1H21: margin 16.2%

ADJUSTED EBITDA ¹

- BRL176.1 million in 2Q22 – up 52.2% from 2Q21: margin 9.0%
- BRL343.4 million in 1H22 – up 53.6% from 1H21: margin 8.9%

ADJUSTED NET PROFIT¹

- BRL54.3 million in 2Q22 – down 30.5% from 2Q21
- BRL153.5 million in 1H22 – up 21.9% from 1H21

CASH CYCLE

- 50 days in 2Q22, 12 days longer than in 2Q21

ROIC¹


- 22.4%

Quarter highlights

- Announcement of the acquisition of **Life, FAMAP and Pro Infusion**, marking Viveo's entry into the sterile solutions handling segment, as the largest player in the southern hemisphere: **BRL449 million** in revenue and **BRL90 million** in combined EBITDA
- Strengthens Viveo's **service channel**

HOSPITALS AND MEDICAL CENTERS

Customer orders and medical prescriptions are received and analyzed by a **proprietary system** for verification and error prevention before the production processes of preparation and handling.



PHARMACEUTICAL INDUSTRY

Medicines and Supplies for handling **sterile solutions** are supplied by the main market players and undergo a **rigorous selection, quality and inspection process**.

TRANSPORT AND DISTRIBUTION LOGISTICS

Transport must be carried out under validated conditions that **guarantee the physical-chemical integrity and sterility of the products** and in accordance with Ordinance 272/98.

HANDLERS

A rigorous quality control is carried out by competent teams that guarantee the **sterility and stability of the products**.

Highly regulated companies, 3+ Resolution Collegiate Board of Anvisa, with careful processes and procedures, automation system to prevent errors






Quarter highlights

- Announcement of the acquisitions of **Boxifarma** and **PHD (Distributor)**;
- Conclusion of the acquisition of **Profarma Specialty**, which offers integrated solutions for distribution, delivery and patient support services;
- Completion of acquisition of **Azimute Med**, specializing in patient support services.

Launch of the Prevena Brand



Consolidated National Presence on a single platform

- Unification of governance and management
- Synergies of processes and structures
- Operational efficiency and unification of service models
- Better experience for customers

The Prevena logo is displayed at the top of a dark teal rounded rectangle. Below it, a list of four bullet points describes the benefits of the consolidated national presence on a single platform.

Synergies: Viveo expects to gradually capture, starting in 2022 and until 2024, estimated synergies of R\$111 million in EBITDA, considering the **17 acquisitions announced since 2021**.

- In 2Q22, **BRL4 million** was captured, of which BRL2.6 million in Costs and BRL1.4 million in General and Administrative Expenses

Year	Estimated synergies	% Captured
2022	BRL12 million	34%
2023	BRL67 million	-
2024	BRL32 million	-
Total	BRL111 million	



Brasil Moody's assigns the rating 'AA.br' to Viveo and the 5th Issue of Debentures

Fifth issue of non-convertible debentures

On July 22, 2022, Viveo completed its fifth issue of non-convertible debentures, in the amount of BRL1 billion, with 5-year maturity and yield of the CDI rate +1.60%. The proceeds will be used to strengthen working capital and/or cash, and/or in lengthening of short-term debt.

Initiatives aligned with the sustainable development goals of the UN Global Compact



- Anti-Bribery System Certification - ISO 37001
- Actions aimed at reducing greenhouse gas (GHG) emissions
 - Purchase of biomass thermal fluid heater, replacing fossil fuel consumption for plant-based consumption: –3,300ton CO2/year or the same as planting 24,000 trees;
 - Installation of a biomass-powered boiler at Viveo's largest industrial plant – in Blumenau/SC.
- Improvement of Diversity and Inclusion indicators
 - Increase in the number of women in leadership positions, from 4.3% of women in management positions in 2020 to 21.1% in 2022. Board of Directors with 1 female member (20%);
 - Internship program: hiring of 30 people. 73% declared themselves to be part of minorities (women, LGBTQIA+ and non-whites), with 80% coming from public schools or scholarship holders in private schools.



Daviso - Sao Paulo/SP

Highlights

Growth initiatives

Hospitals and Clinics

- Development of partnerships with material suppliers for territorial expansion (national level). In Jul/22, start of exclusive distribution of Bedal, with the Cremer brand;
- New business models and strategic partnerships with the pharmaceutical industry in the distribution of medicines, such as: Immunoglobulin, Clexane, RINVOQ and Injectable Dipyron, others.

Retail

- Launch of cosmetics and hygiene products under the Topz brand with the contribution of the Paw Patrol license, one of the best known in the world.

Oncology


- Revenue in this business unit grew 47% in 2Q22 (vs 2Q21), with emphasis on medium and small companies, which represent around 60% of oncology clinics.

Public Market

- 17% growth in 2Q22 (vs 2Q21) of contracts in the portfolio, maintaining our discipline of prior assessment of clients' risk-rating and ROIC of contracts.

Net Revenue

Net Revenue (BRLMM)



Net Revenue of BRL1,946.2 million
Total growth of 32.9% and organic growth of 10.9%



Hospitals and Clinics: +31.5% vs 2Q21 | Organic +13.0%

- Acquisitions, growth in oncology and in contracts in the public market portfolio (maintaining the discipline of prior assessment of the client's risk-rating and ROIC of contracts), in contrast to the drop in the sale of EPIS and products related to the fight against the Covid-19 pandemic.



Laboratories: +9.3% vs 2Q21 | Organic -2.5%

- Prevena: +7.1% organic. 22% increase in the pre-analytical customer base;
- Tecnocold: +10.5% for higher volume of flu vaccines and launch of the new vaccine against Herpes Zosters.



Retail: +55.5% vs 2Q21 | Organic +4.6%


- Acquisition of FW and Daviso and organic growth given the increase in manufactured products, despite the lower sales of PPE and products related to the fight against the Covid-19 pandemic. Scarves +13.8% in 2Q22. Organic ex-COVID 13.9%.



Services: +183.6% vs 2Q21 | Organic +39.9%

- The acquisitions of Cirúrgica Mafra (Dec/21) and PSP from Profarma Specialty (Jun/22), in addition to a month for Boxifarma in 2022 and organic growth due to the advancement of the service agenda with Health Log.

Gross Profit (BRLMM)
Gross Margin (%)




Gross profit growth with profitability gain

- BRL324.1 million gross profit in 2Q22, +47.9% vs 2Q21 (adjusted)
- **Organic growth of 18.7% in 2Q22 vs 2Q21**
- Margin increment on all channels. Highlights:
 - acquired companies have higher margins in relation to the portfolio average;
 - channel of hospitals and clinics with the highest sales in the OL modality;
 - improvement in the margins of manufactured products, especially in the retail channel, as a result of price adjustments;
 - growth of the service channel (today with the best margins in the Company); and
 - beginning of capturing the synergies of the acquired companies..
- Increase in gross margin by 1.7 p.p. compared to 2Q21 (+1.1 p.p. organic), corroborating the strategy of maximizing business profitability.

Adjusted Ebitda


Adjusted EBITDA (BRLMM)
Adjusted EBITDA Margin (%)



Second consecutive quarter with record Adjusted Ebitda Margin

- Adjusted EBITDA of BRL176.1 million, growth of 52.2%.
- **Organic growth of 30.0%**
- Adjusted EBITDA margin of 9.0%, 1.1 p.p. above 2Q21 due to the improvement in gross margin, acquisitions with margins above the portfolio average and capture of synergies.
- Excluded non-recurring expenses/income include, among others:
 - Expenses with M&A and consulting
 - Stock Options
 - Escrow account
 - Tax proceedings, etc


Adjusted Net Income (BRLMM)
Adjusted Net Margin(%)



Increase in leverage to face acquisitions and macro scenario impacted net income in the quarter


- Adjusted net income of BRL54.3 MM, 30.5% decrease compared to 2Q21
- EBITDA growth partially offset by higher net financial expenses of BRL69.1 million
- Adjustments to net income: same non-recurring expenses for EBITDA adjustment, net of IR and CSLL at the rate of 34%

Cash Flow 2Q22 (BRLMM)



- Operational activities:** generated net cash of BRL56.0 million: cash inflow of BRL193.6 million, with R\$ 37.6 million in variations of assets and liabilities, and payments of interest on loans and financings
- Financing activities:** R\$ 395.6 million was spent in the quarter in investment activities, in payment for the acquisitions of Profarma Specialty and other companies
- Financing activities:** applied R\$ 205.6 million in loans and financings, plus payment of dividends for the 2021 business year.

Cash Cycle (days)



Cash Cycle of 50 days in 2Q22
(12 days higher than 2Q21)

The Company's goal is to reduce the cash cycle by the end of 2022

Indebtedness –in 6/30/2022


Debt evolution (BRLMM)

Loans and financing (BRLMilhões)	6/30/22	12/31/2021
Gross Debt ¹	1,999.2	2,131.2
Cash and equivalents	731.8	2,203.7 ²
Debt / (Cash) Net	1,267.5	(72.5)

¹ Considers derivatives

² Considers financial investments

Amortization schedule (BRL thousand)



Average maturity: 4.9 years
average cost: CDI + 2.05% in 2Q22
vs CDI+ 2.19% in 4Q21

Leverage: 1.84x Net Debt/Aj. Ebitda Proforma³

³Proforma numbers: consolidates acquisitions in the results of the last twelve months

Funding in Jul/22 – spread reduction, liability management and debt extension

5th issue of debentures:

- BRL1 billion with CDI rate +1.6% and term of 5 years
- 'AA.br' rating by Moody's



Investor Relations

Leonardo Byrro

CEO

Flávia Carvalho

IR and M&A Director

Luciana Fonseca

IR and Press Manager

Rafaella Wolf

IR Analyst

email: ri@viveo.com.br

www.viveo.com.br/ir